Submit Manuscript  

Article Details

Targeting JAK3 and BTK Tyrosine Kinases with Rationally-Designed Inhibitors

[ Vol. 7 , Issue. 3 ]


Alexei O. Vassilev, Heather E. Tibbles, Darin DuMez, Taracad K. Venkatachalam and Fatih M. Uckun   Pages 327 - 343 ( 17 )


Multifunctional rational drug design of protein tyrosine kinases inhibitors allows a potent drug to be utilized to treat more than one disease for greater patient benefits. Many protein tyrosine kinases (PTK), including Janus kinase 3 (JAK3) and Brutons tyrosine kinase (BTK), have been identified as potential drug targets to treat diverse diseases including cancer and disorders of the immune system. Here we review advances in JAK3 and BTK inhibitors and describe the therapeutic potential of these potent agents in the clinical setting.


Rational Drug Design, Tyrosine Kinases, Inhibitors, JAK3, BTK


Parker Hughes Cancer Center,2848 Patton Road, St. Paul, MN 55113, USA.

Read Full-Text article